{"blog": [], "keywords": [{"value": "Intrexon Corporation", "name": "organizations", "rank": "1", "is_major": "Y"}, {"value": "Biotechnology and Bioengineering", "name": "subject", "rank": "2", "is_major": "Y"}, {"value": "Mosquitoes", "name": "subject", "rank": "3", "is_major": "Y"}, {"value": "Kirk, Randal J (1953- )", "name": "persons", "rank": "4", "is_major": "Y"}, {"value": "Zika Virus", "name": "subject", "rank": "5", "is_major": "N"}, {"value": "Genetic Engineering", "name": "subject", "rank": "6", "is_major": "N"}, {"value": "DNA (Deoxyribonucleic Acid)", "name": "subject", "rank": "7", "is_major": "N"}, {"value": "Synthetic Biology", "name": "subject", "rank": "8", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/03/06/business/a-biotech-evangelist-seeks-a-zika-dividend.html", "document_type": "article", "byline": {"person": [{"lastname": "POLLACK", "firstname": "Andrew", "role": "reported", "organization": "", "rank": 1}], "original": "By ANDREW POLLACK"}, "type_of_material": "News", "multimedia": [{"url": "images/2016/03/06/business/06INTREXON2/06INTREXON2-thumbWide.jpg", "legacy": {"wide": "images/2016/03/06/business/06INTREXON2/06INTREXON2-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/03/06/business/06INTREXON2/06INTREXON2-articleLarge.jpg", "legacy": {"xlarge": "images/2016/03/06/business/06INTREXON2/06INTREXON2-articleLarge.jpg", "xlargeheight": "400", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 400}, {"url": "images/2016/03/06/business/06INTREXON2/06INTREXON2-thumbStandard-v2.jpg", "legacy": {"thumbnail": "images/2016/03/06/business/06INTREXON2/06INTREXON2-thumbStandard-v2.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "2707", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "A diverse biotechnology company hopes its genetically engineered mosquitoes can help stop the spread of a devastating virus. But that\u2019s just a start.", "pub_date": "2016-03-06T00:00:00Z", "news_desk": "SundayBusiness", "headline": {"print_headline": "Seeking a Zika Dividend", "main": "A Biotech Evangelist Seeks a Zika Dividend"}, "print_page": "1", "snippet": "A diverse biotechnology company hopes its genetically engineered mosquitoes can help stop the spread of a devastating virus. But that\u2019s just a start.", "_id": "56dabd8638f0d83eee097acb", "slideshow_credits": null, "abstract": "Randal J Kirk, owner of Intrexon biotech firm, controls what could be effective weapon against mosquitoes carrying Zika virus; has lobbied government to test company's genetically engineered mosquitoes, which have capacity to mate with wild ones and produce offspring that die before adulthood;  successful outcome could end spread of mosquito-born viruses, progress future of synthetic biology and boost Intrexon\u2019s bottom line."}